Scarica l'app Stockscreener
45.95
4.63%
-2.23
Dopo l'orario di chiusura:
46.50
0.55
+1.20%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CRNX Giù?
Forum
Previsione
Crinetics Pharmaceuticals Inc Borsa (CRNX) Ultime notizie
Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock Price Down 8.2%Here's What Happened - MarketBeat
CRNX Stock: Morgan Stanley Raises Price Target to $80 | CRNX Sto - GuruFocus
Crinetics Pharmaceuticals Inc. (CRNX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Morgan Stanley Increases Crinetics Pharmaceuticals (NASDAQ:CRNX) Price Target to $80.00 - MarketBeat
Early PALSONIFY Launch and Atumelnant Data Might Change The Case For Investing In Crinetics (CRNX) - simplywall.st
Crinetics Pharmaceuticals shares down 6.4% after announcing $350 million stock offering - marketscreener.com
Crinetics stock maintains Buy rating at H.C. Wainwright on strong CAH data - Investing.com
Crinetics stock outperforms with strong Palsonify sales, Oppenheimer reiterates $87 target - Investing.com UK
Crinetics Pharma ticks down after announcing $350 mln stock offering - TradingView — Track All Markets
Crinetics Pharmaceuticals stock hits 52-week high at 55.23 USD - Investing.com
Crinetics Buy Rating: Derisked Atumelnant CAH Program and Outperforming Palsonify Launch Signal Undervalued Shares - TipRanks
Crinetics Pharmaceuticals Stock: Biotech Optimism Meets Volatile Reality - AD HOC NEWS
Crinetics shares jump on robust PALSONIFY uptake and encouraging trial results - MSN
Crinetics plans $350 mln public share offering - MSN
Crinetics Reports Strong Palsonify Launch To Date, Positive Phase II CAH Data - Citeline News & Insights
Crinetics Pharmaceuticals announces proposed public offering of common stock - marketscreener.com
Crinetics Pharmaceuticals announces $350M proposed public offering - MSN
Crinetics Highlights Strong PALSONIFY Launch and Trial Progress - TipRanks
Crinetics Pharmaceuticals Plans $350 Million Public Offering - marketscreener.com
Crinetics Pharmaceuticals plans $350 million stock offering - Investing.com India
Crinetics stock ticks lower after announcing $350 million public offering - Investing.com
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock - The Manila Times
Drugmaker seeks $350M to launch PALSONIFY and fund new therapies - Stock Titan
CRNX stock gains, NBIX shares drop on positive results from genetics disorder trial - MSN
CRNX Stock Gains, NBIX Shares Drop On Positive Results From Genetics Disorder Trial - Stocktwits
Crinetics Pharmaceuticals’ Latest Trial Sparks Market Movement - StocksToTrade
Crinetics stock price target raised to $97 from $85 at Jones Trading - Investing.com
Baird reiterates Outperform rating on Crinetics stock as Palsonify launch exceeds expectations - Investing.com
Crinetics stock price target raised to $80 from $77 at Morgan Stanley - Investing.com UK
Crinetics reports robust full-quarter sales for rare disease drug Palsonify - Endpoints News
Crinetics stock price target raised to $90 from $80 at Evercore ISI - Investing.com Canada
Crinetics Pharmaceuticals (NASDAQ:CRNX) Hits New 52-Week HighStill a Buy? - MarketBeat
Crinetics reports Q4 PALSONIFY U.S. preliminary net product revenue of over $5M - TipRanks
Crinetics stock maintains Buy rating at Stifel on positive clinical data - Investing.com Australia
Crinetics (CRNX) Reports Promising Phase II Data for CAH Treatme - GuruFocus
Crinetics Pharmaceuticals touts $5M Palsonify Q4 launch, posts strong atumelnant phase 2 CAH data - MarketBeat
Why Is Crinetics Pharma Stock Soaring Monday?Crinetics Pharmaceuticals (NASDAQ:CRNX) - Benzinga
Crinetics Pharmaceuticals stock hits 52-week high at 55.23 USD By Investing.com - Investing.com South Africa
Crinetics stock soars after strong PALSONIFY launch and positive trial data - Investing.com Canada
Crinetics stock soars after strong PALSONIFY launch and positive trial data By Investing.com - Investing.com South Africa
Why Crinetics Pharmaceuticals Stock Is Sliding Now - TipRanks
Crinetics reports over $5 million in Q4 revenue from acromegaly drug - Investing.com India
Crinetics Announces Strong PALSONIFY Launch Execution and Positive Results for Concurrent Androstenedione Lowering and Glucocorticoid Dose Reduction in Phase 2 Trial of Atumelnant for Congenital Adrenal Hyperplasia - The Manila Times
Crinetics to host conference call on paltusotine and atumelnant data By Investing.com - Investing.com Nigeria
Crinetics to host conference call on paltusotine and atumelnant data - Investing.com
Crinetics Pharmaceuticals to Host Conference Call on January 5, 2026, for PALSONIFY™ Update and Phase 2 Trial Results of Atumelnant - Quiver Quantitative
Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia - The Manila Times
Live briefing to share atumelnant results in congenital adrenal hyperplasia - Stock Titan
Avoiding Lag: Real-Time Signals in (CRNX) Movement - Stock Traders Daily
Crinetics Pharmaceuticals (NASDAQ:CRNX) Upgraded at Wall Street Zen - MarketBeat
Stifel Initiates Coverage of Crinetics Pharmaceuticals (CRNX) with Buy Recommendation - MSN
Crinetics Pharmaceuticals (CRNX) poised for transformational growth in 2026: Piper Sandler - MSN
Moody Aldrich Partners LLC Trims Position in Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
Crinetics stock maintains Buy rating at Stifel on positive clinical data By Investing.com - Investing.com Nigeria
Investors in Crinetics Pharmaceuticals (NASDAQ:CRNX) Have Seen Impressive Returns of 234% Over the Past Five Years - 富途牛牛
Crinetics Pharmaceuticals Earnings Notes - Trefis
Aug Macro: Will Crinetics Pharmaceuticals Inc stock outperform growth indexesMarket Activity Report & High Accuracy Investment Entry Signals - moha.gov.vn
174,077 Shares in Crinetics Pharmaceuticals, Inc. $CRNX Purchased by Rice Hall James & Associates LLC - MarketBeat
2.52%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):